OTC Markets OTCPK - Delayed Quote USD

Alterity Therapeutics Limited (PRNAF)

Compare
0.0036 0.0000 (0.00%)
At close: October 15 at 4:00 PM EDT
Loading Chart for PRNAF
DELL
  • Previous Close 0.0036
  • Open 0.0036
  • Bid 0.0018 x --
  • Ask 0.0037 x --
  • Day's Range 0.0036 - 0.0036
  • 52 Week Range 0.0002 - 0.0068
  • Volume 10,000
  • Avg. Volume 281
  • Market Cap (intraday) 18.884M
  • Beta (5Y Monthly) 0.68
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date Aug 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

alteritytherapeutics.com

10

Full Time Employees

June 30

Fiscal Year Ends

Recent News: PRNAF

View More

Research Reports: PRNAF

View More

Performance Overview: PRNAF

Trailing total returns as of 10/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PRNAF
18.18%
S&P/ASX 200 [XJO]
10.07%

1-Year Return

PRNAF
18.18%
S&P/ASX 200 [XJO]
18.41%

3-Year Return

PRNAF
84.28%
S&P/ASX 200 [XJO]
13.49%

5-Year Return

PRNAF
83.33%
S&P/ASX 200 [XJO]
24.99%

Compare To: PRNAF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PRNAF

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    10.58M

  • Enterprise Value

    2.19M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.03

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -52.66%

  • Return on Equity (ttm)

    -104.47%

  • Revenue (ttm)

    4.02M

  • Net Income Avi to Common (ttm)

    -19.12M

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.64M

  • Total Debt/Equity (mrq)

    1.15%

  • Levered Free Cash Flow (ttm)

    -5.36M

Research Analysis: PRNAF

View More

Company Insights: PRNAF

People Also Watch